Do you recommend holding tyrosine-kinase inhibitors for extracranial metastases being treated with SBRT?
If a patient has thoracic metastases being managed with EGFR TKI, do you refrain from SBRT treatment, do you hold the TKI, or can you treat the patient with both therapies simultaneously?
1 Answer
Mednet Member
Radiation Oncology · Tennessee Oncology
Answered on · Updated on
In general, yes I would recommend holding TKIs during SBRT. Anecdotally from both my own experience and others, there is a small risk of severe pneumonitis in patients on concurrent or recent TKI (much of this with osimertinib which has a reasonably high risk of symptomatic pneumonitis on its own) a...
Join for free or sign in to see the full answer